Solventum (NYSE:SOLV) Hits New 52-Week High – Here’s What Happened

Solventum Corporation (NYSE:SOLV) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $94.16 and last traded at $92.9160, with a volume of 60086 shares traded. The stock had previously closed at $91.06.

Analysts Set New Price Targets

SOLV has been the subject of a number of analyst reports. BTIG Research increased their price target on Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wedbush lifted their price objective on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Stifel Nicolaus upped their target price on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wells Fargo & Company reduced their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.64.

Solventum Price Performance

The firm has a market capitalization of $15.67 billion, a price-to-earnings ratio of 11.26, a PEG ratio of 1.17 and a beta of 0.60. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The business has a 50-day moving average price of $82.81 and a two-hundred day moving average price of $75.61.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm posted $1.69 EPS. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts forecast that Solventum Corporation will post 7.22 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Independent Franchise Partners LLP increased its stake in shares of Solventum by 19.0% in the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after purchasing an additional 2,456,451 shares during the period. California State Teachers Retirement System raised its holdings in shares of Solventum by 5,434.1% during the second quarter. California State Teachers Retirement System now owns 13,234,928 shares of the company’s stock valued at $1,021,075,000 after buying an additional 12,995,776 shares during the last quarter. State Street Corp boosted its position in shares of Solventum by 2.0% during the fourth quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after buying an additional 124,490 shares during the period. Boston Partners boosted its position in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock worth $362,375,000 after buying an additional 763,308 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.